Trial Profile
A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-Comers With Superficial Femoral Artery and Proximal Popliteal Artery Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial disorders; Peripheral arterial occlusive disorders; Peripheral artery restenosis
- Focus Therapeutic Use
- Acronyms REGAL
- 02 Jun 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 1 Jan 2023 to 1 May 2022.
- 03 Jun 2020 Planned primary completion date changed from 1 Jan 2023 to 1 Apr 2022.